Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives Average Rating of “Hold” from Brokerages

Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) have been assigned an average rating of “Hold” from the eleven research firms that are presently covering the firm, Marketbeat.com reports. Eight investment analysts have rated the stock with a hold recommendation, two have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $4.79.

A number of research analysts have weighed in on the stock. HC Wainwright reiterated a “neutral” rating and issued a $2.00 target price on shares of Marinus Pharmaceuticals in a research note on Thursday, November 14th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $4.00 price objective on shares of Marinus Pharmaceuticals in a research note on Thursday, November 14th. Finally, StockNews.com started coverage on Marinus Pharmaceuticals in a research report on Saturday, February 22nd. They issued a “sell” rating for the company.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Virtu Financial LLC bought a new position in Marinus Pharmaceuticals in the 4th quarter worth about $36,000. GABELLI & Co INVESTMENT ADVISERS INC. bought a new position in shares of Marinus Pharmaceuticals in the fourth quarter valued at approximately $54,000. World Investment Advisors LLC purchased a new position in Marinus Pharmaceuticals during the third quarter valued at approximately $104,000. Deltec Asset Management LLC bought a new stake in Marinus Pharmaceuticals during the 4th quarter worth approximately $107,000. Finally, XTX Topco Ltd lifted its stake in Marinus Pharmaceuticals by 1,564.7% in the 4th quarter. XTX Topco Ltd now owns 219,819 shares of the biopharmaceutical company’s stock worth $118,000 after purchasing an additional 206,614 shares in the last quarter. 98.80% of the stock is currently owned by hedge funds and other institutional investors.

Marinus Pharmaceuticals Stock Performance

Shares of NASDAQ:MRNS opened at $0.55 on Thursday. The company has a market capitalization of $30.32 million, a P/E ratio of -0.22 and a beta of 1.03. The company’s 50-day moving average is $0.51 and its 200 day moving average is $0.84. Marinus Pharmaceuticals has a fifty-two week low of $0.22 and a fifty-two week high of $10.50.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.